Dermatologic Research Evaluation and Monitoring of Sleep in Moderate-to-Severe Psoriasis

Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Oct 19, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how sleep affects people with moderate to severe psoriasis, a skin condition that can cause discomfort and other health issues. Researchers want to find out if people with psoriasis have different sleep patterns compared to those without the condition. Since getting good sleep is important for overall health, understanding these differences could help improve the well-being of individuals living with psoriasis.

To participate in this study, you need to be at least 18 years old and diagnosed with moderate to severe plaque psoriasis. Your psoriasis should have been stable for at least three months, and you should be experiencing poor sleep quality. The study is open to all genders and is currently recruiting participants. If you qualify and choose to take part, you can expect to share your sleep experiences and help researchers learn more about the connection between psoriasis and sleep. Your involvement could contribute to better treatment options for people with this condition in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with a diagnosis of moderate to severe plaque type psoriasis confirmed by the principal investigator. Moderate to severe psoriasis will be defined as affected BSA ≥3%. Healthy controls will be age and sex matched (see below) subjects with no prior or current history of psoriasis.
• • 2. Are at least 18 years of age
• • 3. Psoriasis has been stable over the last 3 months
• • 4. Psoriasis is either untreated or treated only with topicals at the current time (see exclusion criteria for washout times)
• • 5. Subjectively reported poor sleep quality using the Pittsburg Sleep Quality Index (PSQI) (defined as a global score \>5)
• • 6. Fluent in English
• • 7. Demonstrate understanding of the study and willingness to participate as evidenced by voluntary informed consent
• Exclusion Criteria:
• • 1. Patients with guttate, erythrodermic, or pustular psoriasis subtypes
• • 2. Having a previous diagnosis of obstructive sleep apnea (OSA) or another medically defined sleep disorder or fall into the intermediate or high-risk groups for having OSA as calculated by the STOP-BANG questionnaire
• • 3. Subjects who have used the following treatments for psoriasis: phototherapy (UVB) in the last 2 weeks, photochemotherapy (PUVA) in the last 4 weeks, oral systemic treatments in the last 4 weeks, biologic immunomodulating agents in the last 12 weeks, or have had exposure to any other investigational drug/device within 30 days prior to study entry
• • 4. Subjects who have used any over the counter or prescription sleep aids within five half-lives of the agent in question.